# A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

> **NCT03395080** · PHASE2 · COMPLETED · sponsor: **Leap Therapeutics, Inc.** · enrollment: 111 (actual)

## Conditions studied

- Endometrial Cancer
- Uterine Cancer
- Ovarian Cancer
- Carcinosarcoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** 300mg DKN-01
- **DRUG:** 600mg DKN-01

## Key facts

- **NCT ID:** NCT03395080
- **Lead sponsor:** Leap Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2020-09-09
- **Final completion:** 2021-01-27
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395080, "A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03395080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*